Aims Programmed death‐ligand 1 (PD‐L1), a potential target for immune checkpoint
inhibitors in various solid neoplasms, has been studied in very few cases of Gall Bladder …

Background Immunomodulatory therapies targeting the interaction between programmed
cell death protein 1 and programmed death-ligand 1 (PD-L1) have become increasingly …

Abstract Background Programmed death ligand 1/2 (PD-L1/PD-L2) expression has been
established as a prognostic factor for various solid tumors and as a predictive factor for PD-1 …

Simple Summary Gallbladder cancer (GBC) is an aggressive malignancy with poor
prognosis. Currently, therapeutic options are mostly limited to palliative chemotherapy …

Background The clinical significance of programmed death 1 and its ligand (PD-L1) as
therapeutic targets has been reported previously. This study aimed to investigate the clinical …

Aims Pembrolizumab has shown promising results for patients with programmed cell death
ligand‐1 (PD‐L1)‐positive advanced biliary tract cancer in an ongoing clinical trial …

Aims Programmed death ligand 1 (PD‐L1) expression has predictive value for response to
immune‐checkpoint inhibitor treatment in urothelial cancer patients. The consistency of PD …

Background: Biliary tract cancer (BTC) is associated with poor prognosis because of its
aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been …

Background Programmed death ligand 1 (PD-L1) has shown potential as a therapeutic
target in numerous solid tumors. Its prognostic significance has also been established in …

Aim We examined the programmed death-ligand 1 (PD-L1) expression in surgically
resected pancreatic adenosquamous carcinoma (PASC) samples. Furthermore, the …